AbbVie Inc (ABBV)
Mexican Exchange · Mexico · prices in MXN · close of 22 Oct 2026
Key indicators
| Last close | MXN 5,307.30 |
|---|---|
| 52-week range | 3,420.00 – 5,339.60 |
| Return, 1 month / 3 months | +16.2% / +21.6% |
| Return, 1 year / 3 years | +29.0% / +121.0% |
| Trend | Uptrend |
| RSI (14) | 77 |
| Volatility (1 year) | 27.1% |
| Worst drawdown (1 year) | -20.6% |
| Average daily value traded | 1.09M MXN |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
AbbVie is a pharmaceutical company based in the United States that develops and markets prescription medicines. Its products treat conditions such as autoimmune diseases, chronic viral hepatitis, and certain cancers, and it also offers medical aesthetics treatments. The company serves patients, physicians and healthcare systems, and its medicines are prescribed in many countries around the world. AbbVie carries out research and development to bring new therapies to market.
On this site AbbVie Inc appears as a stock on the Mexican Exchange (Mexico), code ABBV, with prices in Mexican pesos (MXN). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AbbVie Inc (ABBV) trades on the Mexican Exchange in Mexico. It last closed at MXN 5,307.30 on 22 October 2026.
Its price-based Market X-Ray is 69 out of 100 (a fair price profile), ranking 31 of 361 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 29.0% and over the last three months it rose 21.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Mexican Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 30.8% | ||
| From 52-week high | -0.4% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 21.6% | ||
| 6-month return | 54.1% | ||
| 12-month return, skipping the last month | 11.0% | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.6% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.09M MXN | ||
| Zero-volume days | 30.0% | ||
| Income | 44 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.1% |
|---|---|
| 1 month | +16.2% |
| 3 months | +21.6% |
| 6 months | +54.1% |
| 1 year | +29.0% |
| 3 years | +121.0% |
| 5 years | +188.7% |
Signals
| 50-day / 200-day average | 4,636.08 / 4,057.61 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 65.37 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | MXN 31.9111 |
| 15 Jul 2026 | MXN 30.0778 |
| 15 Apr 2026 | MXN 29.8594 |
| 16 Jan 2026 | MXN 30.6262 |
| 15 Oct 2025 | MXN 30.2691 |
| 15 Jul 2025 | MXN 30.7730 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Mexican Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.